GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2012

FDA Fails to Back Janssen, Bayer’s Xarelto for Acute Coronary Syndrome

  • Partners Janssen Research & Development and Bayer HealthCare failed to get FDA approval to market the anticoagulant Xarelto® (rivaroxaban) for reducing the risk of secondary cardiovascular events among patients with acute coronary syndrome (ACS).The firms have received a complete response letter to the supplemental NDA, which was submitted in December 2011, and say they will work with the agency to address questions.

    The sNDA for Xarelto included data from the Phase III Atlas ACS 2 TIMI 51 trial, which evaluated the use of either rivaroxaban or placebo in addition to standard antiplatelet therapy (low-dose aspirin with or without a thienopyridine) in 15,526 patients with ACS. The data, reported in November 2011, showed that rivaroxaban plus standard therapy reduced the risk of cardiovascular events by 16% over and above that of placebo plus standard therapy. A twice-daily 2.5 mg dose of rivaroxaban reduced the rates of death from cardiovascular causes by 34% in comparison with placebo plus standard therapy (2.7% vs. 4.1%), and reduced the risk of death from any cause by 32% (2.9% vs. 4.5%).

    Originally discovered by Bayer, Xarelto is being jointly developed by Janssen and Bayer HealthCare. Janssen holds marketing rights to the drug in the U.S., and Bayer holds rights to non-U.S. territories. Rivaroxaban is approved in more than 120 countries worldwide for indications including the reduction of DVT in patients having undergone knee or hip replacement surgery, and for reducing the risk of hemorrhagic and thrombotic stroke in patients with nonvalvular atrial fibrillation. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?